The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains

Bioorg Med Chem Lett. 2003 Aug 4;13(15):2573-6. doi: 10.1016/s0960-894x(03)00474-8.

Abstract

Replacement of the pyridylmethyl moiety in indinavir with a pyridyl oxazole yielded HIV-1 protease inhibitors (PI) with greatly improved potency against PI-resistant HIV-1 strains. A meta-methoxy group on the pyridyl ring and a gem-dimethyl methyl linkage afforded compound 10 with notable in vitro antiviral activity against HIV-1 viral strains with reduced susceptibility to the clinically available PIs. Compound 10 also demonstrated favorable in vivo pharmacokinetics in animal models.

MeSH terms

  • Animals
  • Biological Availability
  • Cell Line
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Dogs
  • Drug Resistance, Viral*
  • HIV Protease Inhibitors / chemical synthesis*
  • HIV Protease Inhibitors / pharmacokinetics
  • HIV Protease Inhibitors / pharmacology*
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • Humans
  • In Vitro Techniques
  • Indinavir / pharmacokinetics
  • Indinavir / pharmacology
  • Macaca mulatta
  • Microsomes, Liver / metabolism
  • Rats
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / virology

Substances

  • Cytochrome P-450 Enzyme Inhibitors
  • HIV Protease Inhibitors
  • Indinavir
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A